Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer

NCT02926690 is registered in ClinicalTrials.gov with OncoTherapy Science, Inc. as lead sponsor.

NCT NCT02926690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer
Lead sponsor
OncoTherapy Science, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 29, 2017
Completion date
September 30, 2027
Enrollment
70 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory locally advanced or metastatic breast cancer and triple negative breast cancer